Chinese biotech firm HighTide Therapeutics slashes Hong Kong IPO size by 80% to US$35.6 million

Chinese biopharmaceutical manufacturer HighTide Therapeutics is aiming to raise HK$278 million (US$35.6 million) from an initial public offering in Hong Kong, a fraction of the originally planned US$200 million.